A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma

Must have received: any systemic therapy

have received at least one prior line of treatment

Cannot have received: EO2463 (EO2463)

prior exposure to EO2463

Cannot have received: immunotherapy (immunostimulatory or immunosuppressive therapy)

immunotherapy (meaning immunostimulatory or immunosuppressive therapy; beside excluded, or allowed, compounds per other inclusion/exclusion criteria specifications)

Cannot have received: radionuclide therapy

radionuclide therapy

Cannot have received: radiotherapy

Exception: radiotherapy as only prior treatment is allowed in newly diagnosed, previously untreated cohorts

radiotherapy

Cannot have received: cytoreductive therapy

cytoreductive therapy

Cannot have received: investigational agent

treatment with any other investigational agent within 28 days before the first EO2463 administration

Cannot have received: rituximab or other B cell ablation therapy

received rituximab or other B cell ablation therapy within 8 weeks of start of study treatment

Cannot have received: CAR T-cell therapy

Exception: exclusion only if progressed within 6 months after this therapy

received prior CAR T-cell therapy and progressed within 6 months after this therapy